Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Epithelial–mesenchymal transition (EMT) is known to play an important role in cancer
progression, metastasis and drug resistance. Although there are controversies surrounding …

Resistance to therapy is the major hurdle in the current cancer management. Cancer cells
often rewire their cellular process to alternate mechanisms to resist the deleterious effect …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …

Acquired resistance inevitably limits the curative effects of epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs), which represent the classical paradigm of molecular …

Epithelial/mesenchymal transition (EMT) has emerged as a key regulator of metastasis by
facilitating tumor cell invasion and dissemination to distant organs. Recent evidences …

G protein-coupled receptors (GPCRs) constitute the largest and most diverse protein family
in the human genome with over 800 members identified to date. They play critical roles in …

The hedgehog (Hh) pathway plays a key role in embryonic development and stem cell
programs. Deregulation of the Hh pathway is a key driver of basal cell carcinoma, and …